Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 470 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elevated Risk of Cardiovascular Disease Clear all
Recruiting Not applicable Interventional

Technology-enabled Management Versus Usual Care for Blood Pressure

NCT05479461
View directory record Official record
Conditions
Hypertension
Interventions
Digital Hypertension Management System, Usual Care
Other
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Eatonton, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 22, 2026, 7:38 PM EDT
Not listed No phase listed Observational

Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients

NCT04146727
View directory record Official record
Conditions
Transplant; Failure, Heart, Heart Failure, Congestive, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jul 22, 2026, 7:38 PM EDT
Recruiting Phase 2 Interventional

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

NCT05776979
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

NCT02169791
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
Interventions
MLN9708
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors

NCT03429920
View directory record Official record
Conditions
Cardiovascular Risk Factor, Heart Diseases, Inflammation
Interventions
Q CAN PLUS, Placebo
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
29 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 4 Interventional

Predicting Stroke Risk in ICAD With Novel MRI

NCT05515874
View directory record Official record
Conditions
Intracranial Atherosclerosis
Interventions
Feraheme
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 2 Interventional

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions
(MC-1) Pyridoxal-5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2006 · Synced Jul 22, 2026, 7:38 PM EDT
Recruiting Not applicable Interventional

PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

NCT06445608
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Mechanical Circulatory Support
Device
Lead sponsor
Kardion Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Chandler, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 3 Interventional

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

NCT01006876
View directory record Official record
Conditions
Thromboembolism
Interventions
Coumadin
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 22, 2026, 7:38 PM EDT
Completed No phase listed Observational

Linking Former Inmates to Primary Care

NCT01863290
View directory record Official record
Conditions
Hypertension, Substance Abuse, Asthma, Depression
Interventions
Primary care redesign
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Martinez, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 22, 2026, 7:38 PM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk

NCT05166525
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Interventions
Medically tailored meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • San Rafael, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 22, 2026, 7:38 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children With Diabetes at Risk for Heart Disease.

NCT02275091
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
12 Years to 21 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Jul 22, 2026, 7:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Diet Composition on Weight Change and Metabolic Parameters

NCT01642849
View directory record Official record
Conditions
Obesity, Inflammation
Interventions
high protein diet, high carbohydrate diet
Dietary Supplement
Lead sponsor
University of Tennessee
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

NCT00402506
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions
(MC-1) Pyridoxal 5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Jul 22, 2026, 7:38 PM EDT
Not listed Phase 3 Interventional

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions
lerodalcibep, Placebo
Drug · Other
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Not applicable Interventional

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

NCT01008384
View directory record Official record
Conditions
Atherosclerosis
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Decitabine for High-Risk Sickle Cell Disease

NCT01375608
View directory record Official record
Conditions
Neutropenia, Sickle Cell Disease
Interventions
Decitabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jul 22, 2026, 7:38 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema

NCT05399550
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Balovaptan, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Not applicable Interventional

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

NCT02646488
View directory record Official record
Conditions
Cardiovascular Disease, High Blood Pressure
Interventions
Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

NCT01531374
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 22, 2026, 7:38 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 22, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

NCT00533923
View directory record Official record
Conditions
AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Jul 22, 2026, 7:38 PM EDT